Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of$ 0.50. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2%. A quarter ago, it was expected that this company would post a loss of$ 0.43 per share when it actually produced a loss of $0.54, delivering a surprise of -25.58%. Over the last four quarters, the company ...